Sarepta says ELEVIDYS shows 2-year gains in older Duchenne patients

At WMS 2026, Sarepta said two-year follow-up in boys treated at ages 8-12 showed sustained functional performance versus external controls. It also said safety remained consistent with the established profile, with no new safety signals.